First mRNA vaccine for deadly nipah virus shows promise in early trial
NCT ID NCT05398796
First seen Nov 01, 2025 · Last updated May 21, 2026 · Updated 38 times
Summary
This early-stage study tested an experimental mRNA vaccine (mRNA-1215) for Nipah virus, a serious disease with no approved treatments. Forty healthy adults received two doses of the vaccine and were monitored for safety and immune response over about a year. The vaccine cannot cause Nipah infection, and the main goal was to see if it is safe and well-tolerated.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NIPAH VIRUS INFECTION are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.